Courtney DiNardo, MD, MSCE, Discusses First-in-Human Phase I Study

Courtney DiNardo, MD, MSCE, of the University of Texas MD Anderson Cancer Center, discusses a phase I study investigating LY3410738, a potent, selective, covalent, dual inhibitor of IDH1/2 mutations, in patients with relapsed or refractory IDH1/2 mutated-hematologic cancers. She presented the results of the study at the 2023 American Association for Cancer Research (AACR) Meeting in Orlando, Florida.